This iPSC-based platform can overcome a major limitation in the development of therapeutic strategies for CF, particularly for individuals with rare variants by providing a near limitless supply of patient-specific cells with the ability to quantify CFTR function. This evidence concerns the gene CFTR and cystic fibrosis.